What's in Mabwell (Shanghai) Bioscience Co., Ltd.'s pipeline?

Mabwell (Shanghai) Bioscience Co., Ltd. has 15 drugs in our index: 0 marketed, 0 filed, 5 in Phase 3, 3 in Phase 2, 7 in Phase 1.

Which companies overlap with Mabwell (Shanghai) Bioscience Co., Ltd.'s portfolio?

Top competitors by shared drug class: Innovent Biologics (Suzhou) Co. Ltd., RemeGen Co., Ltd., Celltrion, GlaxoSmithKline, Jiangsu HengRui Medicine Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/mabwell-shanghai-bioscience-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Mabwell (Shanghai) Bioscience Co., Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mabwell (Shanghai) Bioscience Co., Ltd. pipeline: 0 marketed, 0 filed, 5 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 5 Phase 3 3 Phase 2 7 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
9MW0813	9MW0813	phase 3	PD-L1 inhibitor	PD-L1	Oncology
MW032	MW032	phase 3	PD-L1 inhibitor	PD-L1	Oncology
9MW2821	9MW2821	phase 3	PD-L1 inhibitor	PD-L1	Oncology
MW031	MW031	phase 3			Oncology
9MW0311	9MW0311	phase 3	PD-L1 inhibitor	PD-L1	Oncology

Therapeutic area mix

Oncology · 6

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Innovent Biologics (Suzhou) Co. Ltd. · 2 shared drug classes
RemeGen Co., Ltd. · 2 shared drug classes
Celltrion · 2 shared drug classes
GlaxoSmithKline · 2 shared drug classes
Jiangsu HengRui Medicine Co., Ltd. · 2 shared drug classes
Keymed Biosciences Co.Ltd · 2 shared drug classes
3D Medicines (Sichuan) Co., Ltd. · 2 shared drug classes
Shanghai Hengrui Pharmaceutical Co., Ltd. · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Mabwell (Shanghai) Bioscience Co., Ltd.:

Cite this brief

Drug Landscape (2026). Mabwell (Shanghai) Bioscience Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mabwell-shanghai-bioscience-co-ltd. Accessed 2026-05-17.